1. Home
  2. TIL vs BLFY Comparison

TIL vs BLFY Comparison

Compare TIL & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • BLFY
  • Stock Information
  • Founded
  • TIL 2018
  • BLFY 1939
  • Country
  • TIL United States
  • BLFY United States
  • Employees
  • TIL N/A
  • BLFY N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • BLFY Commercial Banks
  • Sector
  • TIL Health Care
  • BLFY Finance
  • Exchange
  • TIL Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • TIL 177.1M
  • BLFY 185.3M
  • IPO Year
  • TIL 2021
  • BLFY N/A
  • Fundamental
  • Price
  • TIL $12.74
  • BLFY $7.80
  • Analyst Decision
  • TIL Strong Buy
  • BLFY Hold
  • Analyst Count
  • TIL 5
  • BLFY 1
  • Target Price
  • TIL $100.67
  • BLFY $10.00
  • AVG Volume (30 Days)
  • TIL 62.5K
  • BLFY 51.0K
  • Earning Date
  • TIL 11-13-2025
  • BLFY 10-29-2025
  • Dividend Yield
  • TIL N/A
  • BLFY N/A
  • EPS Growth
  • TIL N/A
  • BLFY N/A
  • EPS
  • TIL N/A
  • BLFY N/A
  • Revenue
  • TIL N/A
  • BLFY $44,731,000.00
  • Revenue This Year
  • TIL N/A
  • BLFY $19.85
  • Revenue Next Year
  • TIL N/A
  • BLFY $20.18
  • P/E Ratio
  • TIL N/A
  • BLFY N/A
  • Revenue Growth
  • TIL N/A
  • BLFY 11.52
  • 52 Week Low
  • TIL $10.80
  • BLFY $7.79
  • 52 Week High
  • TIL $42.79
  • BLFY $11.38
  • Technical
  • Relative Strength Index (RSI)
  • TIL 31.33
  • BLFY 31.50
  • Support Level
  • TIL $13.53
  • BLFY $8.05
  • Resistance Level
  • TIL $16.00
  • BLFY $8.33
  • Average True Range (ATR)
  • TIL 1.32
  • BLFY 0.23
  • MACD
  • TIL -0.22
  • BLFY -0.02
  • Stochastic Oscillator
  • TIL 7.95
  • BLFY 2.30

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

Share on Social Networks: